[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"chronic-obstructive-pulmonary-disease-copd\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:chronic-obstructive-pulmonary-disease-copd":653},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,99,0,25,[9,46,71,103,119,141,171,204,227,258,279,305,336,360,385,412,433,462,487,510,538,566,587,611,637],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100627330","comparing-ultrasonic-and-conventional-spirometry-in-chronic-respiratory-disease-100627330",false,"NCT07447232","Comparing Ultrasonic and Conventional Spirometry in Chronic Respiratory Disease","A Comparative Study of Ultrasonic and Conventional Spirometers in Patients With Chronic Respiratory Diseases","Inclusion Criteria:\n\n* Adults aged 18 to 80 years.\n* Diagnosed with a chronic respiratory disease (e.g., COPD, asthma, bronchiectasis, or interstitial lung disease).\n* Willing to follow the instructions for using the ultrasonic spirometer.\n* Clinically stable and able to understand the study purpose and procedures, and who provide informed consent.\n\nExclusion Criteria:\n\n* Individuals who, after explanation, are still unable to properly perform the ultrasonic spirometry procedure.\n* Individuals who, after explanation, refuse to participate in the study.\n* Patients with unstable vital signs.\n* Pregnant or suspected pregnant women.","ALL","18 Years","80 Years",{"count":21,"type":22},100,"ESTIMATED","INTERVENTIONAL",[25],"NA","This study compares a handheld ultrasonic spirometer with a standard hospital spirometer in adults with chronic respiratory diseases. Each participant will complete lung function tests using both devices. The study aims to determine whether the ultrasonic device provides accurate and reliable measurements for use in clinical or home settings.",[28,29],"Chronic Obstructive Pulmonary Disease (COPD)","Spirometry",[28,29,31,32],"Ultrasonic Flow Sensor","Pulmonary Function Test","RECRUITING","2026-07-01",{"date":36,"type":37},"2026-07-02","ACTUAL",{"date":39,"type":37},"2026-06-29",{"date":41,"type":22},"2026-07-31",{"name":43,"class":44},"Fu Jen Catholic University","OTHER",1,{"id":47,"slug":48,"hasResults":12,"nctId":49,"briefTitle":50,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":23,"phases":56,"briefSummary":57,"conditions":58,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":4},"100645394","division-of-the-interlobar-fissure-in-patients-who-do-not-respond-to-endobronchial-lung-volume-reduction-100645394","NCT07682168","DIVision of the Interlobar Fissure in Patients Who Do Not Respond to Endobronchial Lung Volume Reduction","DIVIDE","Inclusion criteria\n\n1. Age \\\u003C or equal 75 years\n2. Stable COPD with less than or equal to 10mg prednisolone daily\n3. Nonsmoking for 3 months prior to screening and willing to not smoke during the study duration\n4. Willing and able to complete protocol required study follow-up assessments and procedures\n5. Fit for thoracoscopy under general anaesthesia (surgical and anaesthetic assessment)\n6. Recent (\\\u003C 18 months) endobronchial lung volume reduction (EBLVR) and lack of response defined by:\n\n   1. Persistent symptomatic dyspnoea (mMRC \\>2) which in the patient's view is no better than baseline\n   2. Absence of target lobar collapse with any residual aeration apparent on imaging\n   3. Persistence of (6a) and (6b) following post procedure StratX CT analysis and revisional bronchoscopy.\n\nExclusion criteria\n\n1. Fissure completeness \\\u003C90% on pre EBLVR StratX (i.e less than 10% of fissure to be divided)\n2. Chartis positive for collateral ventilation or not performed\u002Fnot satisfactory at initial EBLVR\n3. Quantitative perfusion of target lobe \\>25% of total on SPECT assessment.\n4. Previous lung surgery or pleurodesis on the target side for LVR.\n5. Clinically significant bronchiectasis -greater than 4 tablespoons mucus per day.\n6. More than 3 COPD exacerbation episodes in the last year.\n7. Evidence of hypercapnia (pCO2 \\>7KPa) - ABG to be performed on admission for index procedure\n8. Clear evidence of pulmonary hypertension (systolic pulmonary arterial pressure \\>45mmHg) or evidence or right ventricular dysfunction as determined by a recent echocardiogram (\\\u003C12mo)\n9. Left ventricular ejection fraction (LVEF) less than 40% as determined by a recent echocardiogram (\\\u003C12mo)\n10. Myocardial infarction within 6 months of screening.\n11. Unable to safely discontinue anticoagulants or platelet activity inhibitors for 7 days.","75 Years",{"count":55,"type":22},15,[25],"Surgical division of fissure is hypothesized to be safe and feasible. However, there is no preparatory study to test this hypothesis. It is logically expected that morbidity from the procedure could be less than standard LVRS and in preparation to a side-to-side trial of fissure division versus standard LVRS, a safety and feasibility study is required to test this hypothesis and inform future trial design.",[28,59,60],"Emphysema","Lung Volume Reduction Surgery","NOT_YET_RECRUITING","2026-06-26",{"date":36,"type":37},{"date":65,"type":22},"2026-08",{"date":67,"type":22},"2028-01",{"name":69,"class":70},"Rocco Bilancia","OTHER_GOV",{"id":72,"slug":73,"hasResults":12,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":77,"eligibilityCriteria":78,"healthyVolunteers":12,"sex":17,"minAge":79,"maxAge":19,"enrollmentInfo":80,"targetDuration":4,"studyType":23,"phases":82,"briefSummary":84,"conditions":85,"keywords":86,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":102},"100583587","phase-3-a-study-to-investigate-the-efficacy-and-safety-of-tezepelumab-in-adult-participants-with-moderate-to-very-severe-copd-d5241c00007-100583587","NCT06878261","A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007)","A Randomised, Double-blind, Placebo-controlled, Parallel Group, Multicentre, Phase III Study to Evaluate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease","JOURNEY","Inclusion Criteria:\n\n1. ≥40 to ≤80 years old\n2. COPD diagnosis ≥1 year,\n3. Post-BD FEV1 ≥ 20% and ≤ 70% PN, FEV1\u002FFVC \\\u003C0.70 at screening\n4. Triple (ICS+LABA+LAMA) or dual inhaled COPD therapy, if triple therapy is considered not appropriate, ≥3 consecutive months prior to V1\n5. ≥2 moderate or ≥1 severe COPD exacerbations in the prior year; At least 1 of 2 moderate exacerbations must require the use of systemic corticosteroids. At least one of the previous exacerbations should be confirmed to have occurred while the participant was on triple or dual inhaled maintenance therapy\n6. EOS ≥ 150 cells\u002FμL during screening\n7. CAT ≥15 at screening\n8. Former or current smokers ≥10 pack-years\n\nExclusion Criteria:\n\n1. Clin. important pulmonary disease or radiological findings suggestive of a respiratory disease other than COPD\n2. Asthma, incl. pediatric, or ACOS\n3. Any unstable disorder that can impact participants safety or study outcomes\n4. Tuberculosis requiring treatment within 12 months prior V2\n5. Malignancies current or past\n\n   Concomitant therapies:\n   * Macrolides (less than 6 months)\n   * Systemic immuno-suppressive, -modulating medications\n6. LTOT \\>4.0 L\u002Fmin or O2 saturation \\\u003C89% despite LTOT","40 Years",{"count":81,"type":22},990,[83],"PHASE3","A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adults with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)",[28],[87,88,89,90,91],"COPD","Moderate COPD","Severe COPD","Very Severe COPD","chronic obstructive pulmonary disease","2026-06-23",{"date":94,"type":37},"2026-06-24",{"date":96,"type":37},"2025-03-25",{"date":98,"type":22},"2029-06-05",{"name":100,"class":101},"AstraZeneca","INDUSTRY",268,{"id":104,"slug":105,"hasResults":12,"nctId":106,"briefTitle":107,"officialTitle":76,"acronym":108,"eligibilityCriteria":78,"healthyVolunteers":12,"sex":17,"minAge":79,"maxAge":19,"enrollmentInfo":109,"targetDuration":4,"studyType":23,"phases":110,"briefSummary":84,"conditions":111,"keywords":112,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":113,"startDateStruct":114,"completionDateStruct":116,"leadSponsor":117,"locationsCount":118},"100583974","phase-3-a-study-to-investigate-the-efficacy-and-safety-of-tezepelumab-in-adult-participants-with-moderate-to-very-severe-copd-d5241c00006-100583974","NCT06883305","A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)","EMBARK",{"count":81,"type":22},[83],[28],[87,88,89,90,91],{"date":94,"type":37},{"date":115,"type":37},"2025-03-18",{"date":98,"type":22},{"name":100,"class":101},301,{"id":120,"slug":121,"hasResults":12,"nctId":122,"briefTitle":123,"officialTitle":124,"acronym":4,"eligibilityCriteria":125,"healthyVolunteers":12,"sex":17,"minAge":79,"maxAge":19,"enrollmentInfo":126,"targetDuration":4,"studyType":23,"phases":128,"briefSummary":131,"conditions":132,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":133,"lastUpdatePostDateStruct":134,"startDateStruct":136,"completionDateStruct":137,"leadSponsor":139,"locationsCount":45},"100643871","phase-1-a-study-of-the-safety-tolerability-pharmacokinetics-and-efficacy-of-kit2014-in-patients-with-moderate-to-severe-copd-100643871","NCT07668518","A Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of KIT2014 in Patients With Moderate to Severe COPD","A Multicentre, Randomised, Double-Blind, Placebo-Controlled, Dose Ranging, Phase 1b\u002F2a Study to Investigate the Safety, Tolerability, Pharmacokinetics and Early Efficacy of Inhaled KIT2014 Over 7 Days of Treatment in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease","Inclusion Criteria:\n\n* Must have given written informed consent before any study-related activities are performed and must be able to understand the full nature and purpose of the study, including possible risks and adverse effects\n* Adult males and females, 40 to 80 years of age (inclusive) at screening.\n* Current or former cigarette smokers with a ≥10 pack-year smoking history\n* Established physician diagnosis of COPD with associated symptoms defined by the GOLD guidelines for ≥ 12 months of screening.\n* FEV1 post-bronchodilator of 40% to 80% of predicted normal at Screening\n* Current symptoms of COPD, including bronchitis and\u002For dyspnoea on moderate exertion at screening.\n\nExclusion Criteria:\n\n* History of life-threatening COPD\n* Chronic obstructive pulmonary disease exacerbation requiring oral or parenteral corticosteroids or hospitalisation within 3 months of Screening\n* Other clinically active, physician diagnosed moderate to severe respiratory disorders that could interfere with study assessments or confound results (e.g., asthma, bronchiectasis, pulmonary fibrosis, interstitial lung diseases, bronchiolitis obliterans, lung cancer, cor pulmonale, pulmonary hypertension, uncontrolled sleep apnoea, active tuberculosis).\n\nOther inclusion\u002Fexclusion eligibility criteria apply.",{"count":127,"type":22},36,[129,130],"PHASE1","PHASE2","Study investigating the safety, tolerability, pharmacokinetics and early efficacy with KIT2014 over 7 days of treatment in moderate to severe chronic obstructive pulmonary disease patients.",[28],"2026-06-19",{"date":135,"type":37},"2026-06-25",{"date":34,"type":22},{"date":138,"type":22},"2027-07-31",{"name":140,"class":101},"Kither Biotech Srl",{"id":142,"slug":143,"hasResults":12,"nctId":144,"briefTitle":145,"officialTitle":146,"acronym":4,"eligibilityCriteria":147,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":148,"targetDuration":4,"studyType":23,"phases":150,"briefSummary":151,"conditions":152,"keywords":156,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":133,"lastUpdatePostDateStruct":163,"startDateStruct":164,"completionDateStruct":166,"leadSponsor":168,"locationsCount":170},"100627695","effects-of-oxygen-supplementation-during-the-6-minute-walk-test-in-chronic-respiratory-failure-or-exertional-hypoxemia-100627695","NCT07451977","Effects of Oxygen Supplementation During the 6-Minute Walk Test in Chronic Respiratory Failure or Exertional Hypoxemia","Evaluation of the Effects of the Oxygen Supplementation During 6-minute Walking Test in Patients With Chronic Respiratory Failure or Exertional Hypoxiemia","Inclusion Criteria:\n\n* Adults aged 18 years or older\n* Diagnosis of chronic respiratory disease admitted for pulmonary rehabilitation\n* One of the following conditions at discharge:\n* Chronic obstructive pulmonary disease with exertional hypoxemia\n* Chronic obstructive pulmonary disease with chronic respiratory failure requiring long-term oxygen therapy\n* Interstitial lung disease with chronic respiratory failure requiring long-term oxygen therapy\n* Clinically stable condition for at least one month\n* Optimized medical therapy during hospitalization\n* Ability to perform the 6-minute walk test\n* Signed informed consent\n\nExclusion Criteria:\n\n* Lung diseases other than chronic obstructive pulmonary disease or interstitial lung disease\n* Resting oxygen flow requirement greater than 4 liters per minute\n* Orthopedic, neurological, or cognitive conditions that may limit walking performance\n* Recent cardiovascular or cerebrovascular events within the previous 3 months",{"count":149,"type":22},114,[25],"The aim of this multicenter crossover trial is to describe the effect of adding a therapeutic dose of exertional oxygen therapy, in terms of exercise performance, gas exchange, heart rate, symptoms perception and subjective easiness of performance, in a cohort of subjects hospitalized in specialized pulmonary rehabilitation centers with a diagnosis of chronic respiratory failure and\u002For exertional hypoxemia due to chronic obstructive pulmonary disease or interstitial lung disease.\n\nResearchers will compare the walking performance during 6-minute walk test performed with the liters of oxygen administered as prescribed at rest (for patients with chronic respiratory failure) or in room air (for patients with exertional hypoxemia only), to the performance during a 6-minute walk test performed with the double the flow rate prescribed at rest, or with 2 L\u002Fmin for patients with exertional hypoxemia only. The two tests will be performed in random order, at least 3 hours apart and no later than 24 hours apart from each other.\n\nThe main outcome will be the difference between the distance walked in the two 6-minute walk test in the two conditions. Furthermore, will be also collected and compared: the oxygen saturation and heart rate every minute, the initial and final dyspnea and fatigue, as assessed by Borg scale, and the easiness of performance through a dedicated questionnaire. The estimated sample size will be 114 patients.\n\nThis study will provide some basis for a more accurate prescription of exercise-related oxygen therapy, offering insights into the phenotype of patients who may derive the greatest benefit from this intervention. It will also stimulate discussion regarding the optimal timing and dosing of oxygen administration during exertion in patients with respiratory failure.",[153,154,28,155],"Chronic Respiratory Failure","Hypoxemia","Interstitial Lung Disease",[157,158,159,160,161,162],"oxygen supplementation","6-minute walk test","chronic respiratory failure","exertional hypoxemia","pulmonary rehabilitation","exercise tolerance",{"date":92,"type":37},{"date":165,"type":37},"2026-04-02",{"date":167,"type":22},"2028-09-30",{"name":169,"class":44},"Istituti Clinici Scientifici Maugeri SpA",6,{"id":172,"slug":173,"hasResults":12,"nctId":174,"briefTitle":175,"officialTitle":176,"acronym":177,"eligibilityCriteria":178,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":179,"targetDuration":4,"studyType":23,"phases":181,"briefSummary":182,"conditions":183,"keywords":185,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":196,"lastUpdatePostDateStruct":197,"startDateStruct":198,"completionDateStruct":200,"leadSponsor":202,"locationsCount":45},"100644076","effect-of-simeox-on-residual-volume-in-copd-patients-with-pulmonary-hyperinflation-100644076","NCT07665931","Effect of Simeox® on Residual Volume in COPD Patients With Pulmonary Hyperinflation","Prospective, Uncontrolled, Single-arm, Interventional Study With Pre-post Intervention Assessment on the Effect of the Simeox® Electro-medical Device on Residual Volume in Patients With COPD and Pulmonary Hyperinflation","SIMEO-RV COPD","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Diagnosis of severe or very severe COPD (GOLD stage 3-4)\n* Documented pulmonary hyperinflation defined by at least one of the following criteria measured by nitrogen wash-out (N₂ wash-out):\n* Residual volume (RV) \\> 150% of predicted\n* Functional residual capacity (FRC) \\> 130% of predicted\n* Total lung capacity (TLC) \\> 120% of predicted\n* RV\u002FTLC ratio \\> 40%\n* Clinical stability (no exacerbations in the 3 weeks prior to enrollment)\n* Patients for whom assessment of the effect of Simeox® on reduction of pulmonary hyperinflation is considered clinically appropriate, in the context of exploratory device use\n* Written informed consent\n\nExclusion Criteria:\n\n* Active or recent pneumothorax (\\\u003C 6 weeks), predisposition to pneumothorax or pneumomediastinum, or known pleural fragility\n* Active or recent gross haemoptysis (\\\u003C 6 weeks) or active pulmonary haemorrhage\n* Haemodynamic instability\n* Unstable cardiovascular conditions, including:\n* Recent myocardial infarction\n* Unstable angina\n* Uncontrolled arrhythmias\n* Unstable heart failure\n* Recent cardiothoracic surgery (\\\u003C 3 months), including oesophageal surgery\n* Recent thoracic trauma or severe acute lung injury\n* Continuous mechanical ventilation, active need for inspiratory assistance, or tracheostomy\n* Neuromuscular diseases with respiratory muscle weakness\n* Inspiratory muscle weakness precluding increased respiratory effort\n* Oropharyngeal or oral muscle weakness\n* Inability to cough effectively, forcefully and autonomously\n* Severe restrictive lung disease (TLC \\\u003C 60% of predicted)\n* Airways at risk of aspiration (e.g. recent nasogastric tube feeding)\n* Uncontrolled gastro-oesophageal reflux disease (GERD)",{"count":180,"type":22},23,[25],"Brief Summary People with severe chronic obstructive pulmonary disease (COPD) often have too much air trapped in their lungs (pulmonary hyperinflation). This makes it hard to breathe and reduces quality of life. This study tests whether a single session with a medical device called Simeox® can reduce the amount of air trapped in the lungs. Simeox® works by applying gentle intermittent negative pressure during exhalation to help air move out of the lungs more easily. Patients with severe or very severe COPD and documented hyperinflation will undergo lung function measurements before and immediately after a 20-minute Simeox® session. The main measurement is the change in residual volume (RV), which is the amount of air left in the lungs after a full exhalation. We will also measure changes in other lung volumes, breathlessness, and any side effects. This is a single-arm pilot study enrolling 23 patients at one center in Italy (ASST Lodi). The study is non-profit and has been approved by the Ethics Committee Comitato Etico Territoriale Lombardia 1 (CET Lombardia 1).",[28,184],"Pulmonary Hyperinflation",[87,184,186,187,188,189,190,191,192,29,193,194,195],"Residual Volume","Air Trapping","Simeox","Intermittent Negative Pressure","airway Clearance","Lung Volumes","Nitrogen Washout","Dyspnea","Respiratory Physiotherapy","Pilot Study","2026-06-18",{"date":94,"type":37},{"date":199,"type":37},"2026-05-05",{"date":201,"type":22},"2026-12",{"name":203,"class":44},"Azienda Socio Sanitaria Territoriale di Lodi",{"id":205,"slug":206,"hasResults":12,"nctId":207,"briefTitle":208,"officialTitle":209,"acronym":4,"eligibilityCriteria":210,"healthyVolunteers":12,"sex":17,"minAge":79,"maxAge":4,"enrollmentInfo":211,"targetDuration":4,"studyType":23,"phases":213,"briefSummary":214,"conditions":215,"keywords":216,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":196,"lastUpdatePostDateStruct":220,"startDateStruct":221,"completionDateStruct":222,"leadSponsor":224,"locationsCount":226},"100644156","study-on-the-impact-of-decolonization-treatment-of-pneumocystis-jirovecii-on-the-frequency-of-acute-exacerbation-in-copd-100644156","NCT07665359","Study on the Impact of Decolonization Treatment of Pneumocystis Jirovecii on the Frequency of Acute Exacerbation in COPD","A Multicenter, Prospective, Double-blind, Randomized Controlled Study on the Impact of Decolonization Treatment on the Frequency of Acute Exacerbation in Patients With Chronic Obstructive Pulmonary Disease Colonized With Pneumocystis Jirovecii","Inclusion Criteria:\n\n* Age 40 and above，male or female；\n* COPD who meet the diagnostic criteria of the Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2026 ( post-bronchodilator FEV1\u002Fforced vital capacity \\[FVC\\] ratio \\\u003C 0.7 and post-bronchodilator FEV1% predicted ≥ 30%), and have documented history of high exacerbation risk (Group E, defined as exacerbation history of ≥ 1 moderate or severe acute exacerbation within 12 months prior to inclusion)；\n* Background triple therapy (ICS + LABA + LAMA) for 3 months prior to randomization with a stable dose of medication for ≥1 month prior to inclusion; Double therapy (LABA + LAMA) allowed if ICS is contraindicated；\n* PCR detection of Pneumocystis jirovecii in induced sputum is positive；\n* Informed consent\n\nExclusion Criteria:\n\n* Allergic to TMP, SMX or sulfonamide drugs；\n* There are pneumonia or other infections that require long-term use of antibacterial drugs (such as tuberculosis, NTM, other fungi, etc.)；\n* Having used antibiotics within the previous 4 weeks prior to screening；\n* Experience of AECOPD events within the previous 4 weeks prior to screening;\n* Having a definite immunodeficiency disorder or receiving immunosuppressive therapy (such as HIV, agranulocytosis, solid organ or hematopoietic stem cell transplantation, malignant tumors, using long-term high-dose hormones \\> 20mg\u002Fday prednisone equivalent for more than 4 weeks)；\n* Severe liver and kidney dysfunction (ALT\u002FAST \\> 3 times the upper limit of normal value, eGFR \\\u003C 60 mL\u002Fmin\u002F1.73m²)；\n* Pregnant, lactating women or those planning to become pregnant;\n* Folic acid deficiency-induced microcytic anemia;\n* Currently using coumarin, phenytoin, pioglitazone, repaglinide, rosiglitazone, glipizide or glibenclamide;\n* Currently participating in other interventional clinical studies；",{"count":212,"type":22},630,[25],"Previous researches have found the common colonization of Pneumocystis jirovecii (Pj) in the airways of people with chronic obstructive pulmonary disease (COPD). And this colonization may exacerbate airway inflammation and increase the frequency of acute exacerbation in people with COPD.\n\nThe goal of this clinical trial is to study if \"decolonization treatment\" (that is, removing these colonizing Pj) works to improve the prognosis of COPD colonized by Pj in adults. The main question it aims to answer is:\n\n* Does the Trimethoprim-Sulfamethoxazole (TMP-SMX, an antibiotics) decolonization treatment reduce the frequency of acute exacerbation in participants with COPD colonized by Pj who have a high risk of acute exacerbation.\n\nResearchers will compare TMP-SMX to a placebo (a look-alike substance that contains no drug) to see if TMP-SMX works to reduce the frequency of acute exacerbation of COPD.\n\nParticipants will:\n\n* Take drug TMP-SMX or a placebo 2 tablet every day for 4 weeks.\n* Visit the clinic after 2 weeks, 1 month, 3 months, 6 months and 12 months for survey questions, checkups and tests.\n* Keep a diary of their symptoms and the number of times they experience acute exacerbations",[28],[217,218,219],"Chronic Obstructive Pulmonary Disease","Pneumocystis jirovecii","Trimethoprim-Sulfamethoxazole",{"date":94,"type":37},{"date":34,"type":22},{"date":223,"type":22},"2029-05-01",{"name":225,"class":44},"Second Affiliated Hospital, School of Medicine, Zhejiang University",20,{"id":228,"slug":229,"hasResults":12,"nctId":230,"briefTitle":231,"officialTitle":232,"acronym":4,"eligibilityCriteria":233,"healthyVolunteers":12,"sex":17,"minAge":234,"maxAge":19,"enrollmentInfo":235,"targetDuration":4,"studyType":23,"phases":237,"briefSummary":238,"conditions":239,"keywords":242,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":249,"lastUpdatePostDateStruct":250,"startDateStruct":252,"completionDateStruct":254,"leadSponsor":256,"locationsCount":45},"100607998","mindful-breath-for-people-with-copd-100607998","NCT07195838","Mindful-Breath for People With COPD","Effects of a Hybrid, Personalised Mindfulness-optimised Pulmonary Rehabilitation (Mindful-Breath) Programme for Active Living for People With Chronic Obstructive Pulmonary Disease: A Pilot Randomised Controlled Trial","Inclusion Criteria:\n\n* Age: 50-80 years\n* Sex: Male or female\n* Education level: Primary or above\n* Diagnosis: COPD (Baseline FEV1 \\\u003C80% and FEV1\u002FFVC \\\u003C70% of predicted normal values)\n* Severity of COPD: Stage I to IV\n* Group of COPD: Group B, or E, based on 2024 GOLD guideline (36)\n* Clinical stability: No acute exacerbation in the past 4 weeks. Patients with recent acute exacerbation in the past 4 weeks will be screened again in subsequent follow-up.\n* Moderate stress: PSS score ≥14 (28)\n* Access to a mobile device (e.g., a smartphone, tablet, or laptop) with internet connectivity\n* Ability to read, communicate, and provide written consent in Chinese.\n\nExclusion Criteria:\n\n* Engaging in \\>60 minutes\u002Fweek of moderate PA based on American Lung Association guidelines\n* Recent or ongoing receipt of other pharmacological\u002Fbehavioral trials within the past 3 months\n* Contraindications or severe comorbidities that may limit full participation (mental diseases, deafness, limb activity disorder, coronary heart disease, arterial aneurysm, uncontrolled hypertension, pregnancy, etc)\n* Co-existing respiratory diseases (Asthma\u002Finterstitial lung disease\u002Fbronchiectasis) or active malignancies\n* Very severe COPD requiring long-term oxygen therapy or home non-invasive ventilation","50 Years",{"count":236,"type":22},60,[25],"Individuals living with chronic obstructive pulmonary disease (COPD) often suffer from stress and behavioral risks such as physical inactivity. In an attempt to promote healthy behaviors and overall wellbeing among this particular population, this study aims to develop and evaluate a personalized Mindful-Breath intervention combining telehealth technology and mindfulness for COPD patients. This is an assessor-blinded, two-arm exploratory randomized controlled trial with a sequential mixed-method design. A total of 60 participants will be recruited and randomly assigned to either intervention or control group using 1:1 ratio. Intervention group will go through 8 weekly 60-min hybrid group sessions, combining mindfulness-based pulmonary rehabilitation and lifestyle modification. Personalized mindfulness-based lifestyle counselling through instant messages with chat-based support throughout the 8-week intervention period will also be provided. Control group will receive a single in-person 60-min group session on general education on pulmonary rehabilitation and lifestyle modification and will only receive reminder messages for follow-ups. Variables such as time spent on physical activity, lung function, perceived stress, symptom burden and health-related quality of life will be collected at three time-points (T0: baseline, prior to randomization; T1: immediate post-intervention; T2: 3-month post-intervention).",[240,241,28],"Mindfulness","Pulmonary Rehabilitation",[243,161,91,244,245,246,247,248],"mindfulness","RCT","lifestyle modification","mHealth","EMI","physical inactivity","2026-06-15",{"date":251,"type":37},"2026-06-16",{"date":253,"type":37},"2025-09-30",{"date":255,"type":22},"2027-06-30",{"name":257,"class":44},"The University of Hong Kong",{"id":259,"slug":260,"hasResults":12,"nctId":261,"briefTitle":262,"officialTitle":263,"acronym":264,"eligibilityCriteria":265,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":266,"targetDuration":4,"studyType":23,"phases":268,"briefSummary":269,"conditions":270,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":271,"lastUpdatePostDateStruct":272,"startDateStruct":274,"completionDateStruct":275,"leadSponsor":277,"locationsCount":45},"100641639","effect-of-exercise-order-during-pulmonary-rehabilitation-on-muscle-strength-in-patients-with-copd-100641639","NCT07655011","Effect of Exercise Order During Pulmonary Rehabilitation on Muscle Strength in Patients With COPD","Effect of Intra-Session Training Order of Cardiorespiratory Endurance Work and Muscle Strengthening in COPD Patients","ISTOR-COPD","Inclusion Criteria:\n\n* Age ≥ 18 years\n* COPD GOLD stages 2 to 4\n* Admitted for pulmonary rehabilitation in a participating center\n* Ability to read and speak French\n* Written informed consent\n* Affiliation with a social security system\n\nExclusion Criteria:\n\n* Legal protection (guardianship or trusteeship)\n* Pregnancy beyond the second trimester\n* Musculoskeletal disorders affecting lower limb strength or walking performance\n* Vascular disease limiting walking distance\n* Cardiac contraindication to pulmonary rehabilitation",{"count":267,"type":22},138,[25],"Chronic Obstructive Pulmonary Disease (COPD) is a chronic multisystem disease frequently associated with peripheral muscle dysfunction, which is strongly linked to prognosis and survival. Pulmonary rehabilitation is a cornerstone of COPD management and includes both cardiorespiratory endurance training and muscle strengthening exercises. Although these components are routinely combined within rehabilitation programs, the optimal order in which they should be performed during the same training session remains unclear.\n\nIn healthy individuals, performing endurance and strength exercises in different sequences within a single session may influence muscular adaptations, a phenomenon referred to as the intra session interference effect. This effect has never been studied in patients with COPD undergoing pulmonary rehabilitation. Given the high prevalence and clinical importance of muscle weakness in COPD, optimizing exercise prescription may improve functional outcomes and long term benefits.\n\nThis multicenter randomized controlled trial aims to compare two pulmonary rehabilitation strategies that differ only in the order of exercise administration. Participants with moderate to severe COPD will be randomly assigned to perform either muscle strengthening before endurance training or endurance training before muscle strengthening during each rehabilitation session.\n\nThe primary objective is to evaluate the impact of exercise order on lower limb muscle strength, assessed by the Five Times Sit to Stand test at the end of the rehabilitation program. Secondary objectives include assessment of exercise capacity, dyspnea, muscle and inflammatory biomarkers, tolerance, and adherence to the rehabilitation program, as well as follow up evaluations up to 12 months after completion.\n\nThe results of this study are expected to provide evidence to optimize pulmonary rehabilitation programs for patients with COPD and to inform clinical practice regarding exercise sequencing.",[28],"2026-06-12",{"date":273,"type":37},"2026-06-17",{"date":65,"type":22},{"date":276,"type":22},"2030-01",{"name":278,"class":44},"CHU de Reims",{"id":280,"slug":281,"hasResults":12,"nctId":282,"briefTitle":283,"officialTitle":284,"acronym":4,"eligibilityCriteria":285,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":286,"targetDuration":4,"studyType":288,"phases":4,"briefSummary":289,"conditions":290,"keywords":293,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":297,"lastUpdatePostDateStruct":298,"startDateStruct":299,"completionDateStruct":301,"leadSponsor":303,"locationsCount":45},"100643158","measurements-before-and-after-participation-in-a-health-intervention-programme-in-halsnaes-municipality-100643158","NCT07641309","Measurements Before and After Participation in a Health Intervention Programme in Halsnaes Municipality","Effects for Individuals Following a Health Intervention Programme in Halsnaes Municipality; A Sub-project Under the Initiative: Quality Development in Community Healthcare: Steno Tvaers","Inclusion Criteria:\n\n* Diagnosis of type 2 diabetes, chronic obstructive pulmonary disease, or cardiovascular disease\n* At or above 18 years of age\n* Offered a health programme provided by Halsnæs Municipality\n\nExclusion Criteria:\n\n* None",{"count":287,"type":22},194,"OBSERVATIONAL","Based on the Danish Health Authority's quality standards for municipal prevention services for citizens with chronic diseases, Steno Diabetes Center Copenhagen (SDCC), Halsnaes Municipality, North Zealand Hospital, and others have entered into a cross-sectoral collaboration entitled \"Quality Development in Community Healthcare: Steno Tvaers - A Model for Differentiated Health Interventions for Citizens with Diabetes, Chronic Obstructive Pulmonary Disease (COPD), or Cardiovascular Disease sased in Halsnaes Municipality\" (hereafter referred to as Steno Tvaers). Based in Halsnaes Municipality, the aim of Steno Tvaers is to adapt and, where relevant, supplement existing healthcare services in the municipality to better meet the needs of and reach all citizens with chronic diseases.\n\nThe present sub-project \"Measurements before and after participation in a health intervention programme in Halsnaes Municipality\" (hereafter referred to as the sub-project) is conducted within the framework of Steno Tvaers. The objective of the current sub-project is to assess whether citizens with diabetes, COPD, or cardiovascular disease, who participate in a health intervention programme in Halsnaes Municipality, improve their functional capacity.\n\nFor citizens with diabetes, the sub-project also aims to assess whether participation in the programme results in improved blood glucose concentration, blood pressure, and medical adherence.\n\nThe hypothesis of the sub-project is that the organizational changes planned within Steno Tvaers for successful implementation of the quality standards will lead to a resulting health effect at the individual level.\n\nIt is important to note that the healthcare interventions are existing services, the quality and uptake of which are being enhanced through the Steno Tvaers project, and that this does not involve testing a new intervention. Participation in the project therefore only involves contributing data that are already being collected by the municipality, supplemented by responses to two questionnaires. For citizens with diabetes, this is further supplemented with data on blood glucose (HbA1c), blood pressure, attendance at follow-up visits with general practitioners and in hospital settings, as well as adherence to prescribed medication. Data are collected at the beginning and at the end of a health intervention programme, and at the end of the project, the data will be linked to selected national registers.",[291,28,292],"Type 2 Diabetes","Cardiovascular Disease",[294,295,296],"primary and community care sector","decentralized healthcare system","local healthcare system","2026-06-10",{"date":271,"type":37},{"date":300,"type":37},"2026-05-28",{"date":302,"type":22},"2027-09",{"name":304,"class":44},"Steno Diabetes Center Copenhagen",{"id":306,"slug":307,"hasResults":12,"nctId":308,"briefTitle":309,"officialTitle":310,"acronym":311,"eligibilityCriteria":312,"healthyVolunteers":313,"sex":17,"minAge":18,"maxAge":314,"enrollmentInfo":315,"targetDuration":4,"studyType":288,"phases":4,"briefSummary":317,"conditions":318,"keywords":323,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":297,"lastUpdatePostDateStruct":330,"startDateStruct":331,"completionDateStruct":333,"leadSponsor":334,"locationsCount":45},"100642831","breathlessness-perceptions-within-respiratory-diseases-100642831","NCT07648082","Breathlessness Perceptions Within Respiratory Diseases","Exploring Differences in Breathlessness Perceptions Within Respiratory Diseases","BiRD","Inclusion Criteria:\n\n* • Aged 18 or over up to 100\n\n  * Known respiratory diagnosis\\* OR Healthy control\\*\\*\n  * Ongoing symptoms of breathlessness defined as ≥2 MRC dyspnoea scale\n  * Able to communicate in English\n  * Able to attend two study visits\n  * Able to provide written informed consent\n\n    * Known respiratory diagnosis could include, but is not limited to, COPD, Asthma, Bronchiectasis or ILD.\n    * Healthy controls are required to have an absence of a functionally limiting condition such as respiratory, cardiovascular, or musculoskeletal.\n\nExclusion Criteria:\n\n* • Unstable disease or undergoing investigations for unexplained symptoms\n\n  * Undergone a surgery within past six weeks\n  * Contraindications for exercise outlined by ACSM guidelines (Unstable CVD, hypertension etc)\n  * BMI ≥ 35kg\u002Fm2\n  * Unable to communicate in English\n  * Unable to provide written informed consent\n  * Unable to abstain from smoking for 8 hours prior to testing",true,"100 Years",{"count":316,"type":22},75,"Breathlessness is a complex symptom that results in poor quality of life, increased hospitalisations and increased mortality. Breathlessness is influenced by physiological, psychological and functional factors but these are poorly explored. There are also unexplored phenomenon's such as breathing pattern. Therefore, this study aims to understand the influences of physiology, psychology, function and breathing pattern on health related quality of life in those with a respiratory disease compared to healthy controls. This project is a cross-sectional cohort study including those with a known respiratory disease and experiencing breathlessness, compared to non-breathless healthy controls. The investigators will measure your physiology through spirometry (a breathing test that tells us about their lung function), psychology through questionnaires, function through an exercise test and breathing pattern using opto-electrictronic plethysmography (markers are placed on your chest to see how participants breathe while exercising). This will be conducted over two visits. The investigators will recruit participants from clinics at the University Hospitals of Leicester NHS Trust. The investigators are aiming to recruit 50 participants with a respiratory disease and 25 healthy controls. The results of this study will help us understand breathlessness in more detail in order to be able to develop better treatments.",[28,319,320,321,322],"Asthma (Diagnosis)","Interstitial Lung Disease (ILD)","Bronchiectasis","Breathing Pattern Disorder",[324,325,326,327,328,329],"Breathlessness","OEP","Cardiopulmonary Exercise Testing","Respiratory diseases","Heart rate variability","Breathing patterns",{"date":249,"type":37},{"date":332,"type":37},"2025-06-06",{"date":34,"type":22},{"name":335,"class":44},"University Hospitals, Leicester",{"id":337,"slug":338,"hasResults":12,"nctId":339,"briefTitle":340,"officialTitle":341,"acronym":342,"eligibilityCriteria":343,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":344,"targetDuration":4,"studyType":23,"phases":346,"briefSummary":347,"conditions":348,"keywords":349,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":352,"lastUpdatePostDateStruct":353,"startDateStruct":354,"completionDateStruct":356,"leadSponsor":358,"locationsCount":45},"100642584","evaluation-of-the-benefits-of-hypnosis-in-improving-the-quality-of-life-of-patients-with-chronic-obstructive-pulmonary-disease-copd-suffering-from-persistent-dyspnea-100642584","NCT07637604","Evaluation of the Benefits of Hypnosis in Improving the Quality of Life of Patients With Chronic Obstructive Pulmonary Disease (COPD) Suffering From Persistent Dyspnea","Evaluation of the Benefits of Hypnosis in Improving the Quality of Life of Patients With Chronic Obstructive Pulmonary Disease (COPD) Suffering From Persistent Dyspnea: a Multicenter Randomized Controlled Trial","HYPNODYS","Inclusion Criteria:\n\n* Age \\>18 years\n* COPD (any etiology), referred by a pulmonologist and managed according to GOLD 2024 guidelines except for pulmonary rehabilitation that is not required\n* Outpatient follow-up\n* Residing in Paris or the inner suburbs for centers located within the city limits, or within a 30-minute drive for centers located outside the city limits of Paris.\n* Dyspnea rated as mMRC 3 or 4\n* Having signed an informed consent form\n\nExclusion Criteria:\n\n* Vulnerable individuals (under legal guardianship or curatorship) or deprived of liberty\n* Pregnant or breastfeeding women\n* Absolute or relative contraindication to the 6 minutes walk test, spirometry or body plethysmography\n* Current COPD exacerbation or exacerbation resolved less than one week ago\n* Psychosis or other psychiatric disorder likely to interfere with study participation\n* Profound hearing impairment\n* Cognitive impairment\n* Use of psychedelic substances (ex: LSD (Lysergic acid diethylamide), psilocybin, etc.)\n* Current participation in interventions that may be related to hypnosis: any kind of meditation, relaxation, sophrology, heart coherence training, yoga, Qi Gong, holotropic breathing, EMDR (Eye Movement Desensitization and Reprocessing) or any psychotherapies involving eye movements, as well as shamanic practices and brief psychotherapies or cognitive-behavioral therapies\n* Previous management of dyspnea using hypnosis\n* Ongoing pulmonary rehabilitation (physiotherapy outside a structured rehabilitation program initiated before study inclusion is not an exclusion criterion)\n* Inability to be reached by phone or teleconsultation\n* Lack of health insurance (French social security) coverage\n* Participation in another clinical trial\n* End of life",{"count":345,"type":22},154,[25],"Chronic Obstructive pulmonary Disease (COPD) is a common progressive disorder characterized by persistent airflow limitation. It is usually caused by exposure to tobacco smoke, toxic particles, or toxic gases. COPD is characterized by cough, sputum production, and dyspnea, which is the cardinal symptom and is included in the criteria for severity. Dyspnea is a major source of suffering and disability, especially when it persists at rest.\n\nDespite proper medical treatment, many patients continue to suffer from persistent dyspnea that significantly impairs their daily functioning and quality of life. Complementary approaches such as yoga and relaxation techniques are therefore recommended by some experts. Hypnosis is one of these practices. It has been shown to be effective in the management of both acute and chronic pain and it can abolish several types of experimentally induced dyspnea in healthy volunteers. In adults with COPD, a single hypnosis session has been shown to reduce anxiety immediately, though only temporarily. However, according to a recent retrospective study, a median of three hypnosis sessions increases the distance covered in the 6-minute walk test in COPD patients.\n\nThe investigators therefore hypothesize that several hypnosis sessions will improve the quality of life of adult outpatients with COPD who suffer from persistent dyspnea. The study plans to recruit 154 patients with severe dyspnea (mMRC(modified Medical Research Council Dyspnea Scale) 3 or 4). They will be randomly assigned to either the experimental group or the control group. Patients in the experimental group will participate in 5 sessions of medical hypnosis spaced 7 ± 2 days apart. The first hypnosis session will take place at the end of the enrollment visit. The final session will be held via teleconsultation. Four standardized telephone calls, spaced 7 ± 2 days apart, will replace the hypnosis sessions in the control group. The primary outcome of the study will be the evolution of quality of life, assessed 6 weeks after the start of the study as compared to baseline. Secondary outcomes will focus on changes in exercise capacity, dyspnea, anxiety, depression, dyspnea-related catastrophizing, self-efficacy, and pleasure in life.",[28,193],[28,350,351],"Dyspnea,","Hypnosis","2026-06-05",{"date":297,"type":37},{"date":355,"type":22},"2026-09-01",{"date":357,"type":22},"2029-12-15",{"name":359,"class":44},"Assistance Publique - Hôpitaux de Paris",{"id":361,"slug":362,"hasResults":12,"nctId":363,"briefTitle":364,"officialTitle":365,"acronym":366,"eligibilityCriteria":367,"healthyVolunteers":12,"sex":17,"minAge":79,"maxAge":4,"enrollmentInfo":368,"targetDuration":4,"studyType":23,"phases":370,"briefSummary":371,"conditions":372,"keywords":373,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":376,"lastUpdatePostDateStruct":377,"startDateStruct":379,"completionDateStruct":381,"leadSponsor":383,"locationsCount":384},"100599303","phase-2-a-study-to-investigate-the-effect-of-azd6793-in-participants-with-moderate-to-very-severe-chronic-obstructive-pulmonary-disease-100599303","NCT07082738","A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease","A Multicentre, Parallel-group, Phase IIb, Randomised, Double-blind, Placebo-controlled, 3-Arm, 24-Week Study to Evaluate the Efficacy and Safety of AZD6793 Tablets in Adult Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (PRESTO)","PRESTO","Inclusion Criteria:\n\n* Participant must be ≥40 years of age at the time of signing the informed consent.\n* Documented primary diagnosis of COPD for at least 12 months prior to enrolment.\n* Pre-BD FEV1\u002FFVC \\\u003C 0.7 at Visit 1 and pre- and post-BD FEV1\u002FFVC \\\u003C 0.7, and post-BD FEV1 ≥ 25% to \\\u003C 80% of predicted normal at Visit 2.\n* Documented history of ≥ 2 moderate or ≥ 1 severe COPD exacerbations in the 12 months prior to screening.\n* Documented stable regimen of inhaled triple maintenance therapy or inhaled dual maintenance therapy for ≥ 3 months prior to screening.\n* CAT score ≥ 10 at Visit 1.\n* Current or ex-smokers with a cigarette smoking history of ≥ 10 pack-years.\n* Participants who are clinically stable and free from an exacerbation of COPD for 4 weeks prior to Visit 1 and are also exacerbation free for at least 4 weeks (28 days) prior to Visit 3 (randomisation).\n* Negative pregnancy test at Visit 1 and Visit 3 for Women Of Child-Bearing Potential (WOCBP).\n\nExclusion Criteria:\n\n* Clinically important pulmonary disease other than COPD (eg, asthma \\[current diagnosis per GINA or other accepted guidelines\\], active pulmonary infection, clinically significant bronchiectasis when bronchiectasis is the predominant diagnosis, pulmonary fibrosis, cystic fibrosis, hypoventilation syndrome associated with obesity, lung cancer, alpha-1 antitrypsin deficiency or primary ciliary dyskinesia).\n* Radiological findings suggestive of a respiratory disease other than COPD that is significantly contributing to the participant's respiratory symptoms.\n* Any unstable disorder, including, but not limited to, CV, gastrointestinal, hepatic, renal, neurological, musculoskeletal, infectious, endocrine, metabolic, haematological, psychiatric disorder, major physical and\u002For cognitive impairment.\n* Significant left heart failure.\n* Unstable angina, acute coronary syndrome\u002Facute myocardial infarction or coronary intervention with percutaneous coronary intervention\u002Fcoronary artery bypass graft within 6 months of randomisation, uncontrolled arrhythmia, or cardiomyopathy, clinically significant aortic stenosis, or signs of pulmonary oedema or volume overload.\n* Pulmonary arterial hypertension, either idiopathic or due to connective tissue or thromboembolic disease.\n* History of another underlying condition that predisposes the participant to infections.\n* History of ulcerative colitis, Crohn's disease, or microscopic colitis diagnosed by either a gastroenterologist or by histopathology.\n* Abnormal laboratory findings.\n* Participants with evidence of active liver disease and\u002For evidence of chronic liver disease.\n* Participants with history of HIV infection or who test positive for HIV.\n* History of lung volume reduction surgery.\n* Current or history of malignancy within 5 years before the screening visit.",{"count":369,"type":22},987,[130],"This Phase IIb dose-ranging study will evaluate the efficacy and safety of 2 different doses of AZD6793 compared with placebo tablets in participants with moderate to very severe chronic obstructive pulmonary disease.",[28],[87,88,89,90,91,374,375],"AZD6793","IRAK4 Inhibitor","2026-06-03",{"date":378,"type":37},"2026-06-04",{"date":380,"type":37},"2025-06-27",{"date":382,"type":22},"2027-11-05",{"name":100,"class":101},366,{"id":386,"slug":387,"hasResults":12,"nctId":388,"briefTitle":389,"officialTitle":390,"acronym":391,"eligibilityCriteria":392,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":393,"targetDuration":4,"studyType":23,"phases":395,"briefSummary":396,"conditions":397,"keywords":398,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":403,"lastUpdatePostDateStruct":404,"startDateStruct":406,"completionDateStruct":408,"leadSponsor":410,"locationsCount":45},"100589617","intermittent-intrapulmonary-deflation-and-dyspnea-following-exercise-in-people-with-chronic-obstructive-pulmonary-disease-100589617","NCT06956742","Intermittent Intrapulmonary Deflation and Dyspnea Following Exercise in People With Chronic Obstructive Pulmonary Disease","Effect of Intermittent Intrapulmonary Deflation on the Sensory Dimension of Dyspnea After Exercise in Patients With Chronic Obstructive Pulmonary Disease: A Double-blind, Randomized Crossover Study","DEFLA-DYSPNEA","Inclusion Criteria:\n\n* Age \\> 18 years;\n* COPD stage GOLD II to IV;\n* Had completed a pulmonary rehabilitation programme at the investigational site;\n* 6-minute walk test \\\u003C 350 meters before and\u002For after completing the pulmonary; rehabilitation program;\n* mMRC dyspnea scale ≥ 2;\n* Pulmonary hyperinflation (ratio between residual volume to total lung capacity superior to 50%, and either total lung capacity superior to 130% or functional residual capacity superior to 130%);\n* With or without oxygen supplementation;\n* Stable condition (no exacerbation or change in treatment in the last 4 weeks);\n* Naïve to intermittent intrapulmonary deflation.\n* Regulatory criteria (social security affiliation; adult patient who has read and understood the information letter and signed the informed consent form).\n\nNon-inclusion Criteria:\n\n* Pregnant women or likely to be;\n* Patients under guardianship or curatorship;\n* Inability to consent;\n* Primary diagnosis of another chronic obstructive respiratory disease such as asthma or primary bronchiectasis;\n* Orthopedic, neurological, vascular, or neuromuscular conditions that limit walking or require walking aids;\n* Severe or unstable cardiovascular disease (uncontrolled cardiac arrhythmias, severe heart failure, recent myocardial infarction, unstable angina);\n* Patients actively requiring assistance with inspiration (e.g. ventilatory assistance with endotracheal tube, tracheostomy tube, or ventilated with a mask; patients with neuromuscular disease with respiratory muscle weakness; patients with inability to cough forcefully and independently);\n* Hemodynamic instability;\n* Recent pneumothorax (within the last 3 months);\n* Recent pulmonary or upper airway surgery (within the last month);\n* Referral to a pulmonary rehabilitation program in preparation for thoracic surgery (lung volume reduction, lung transplantation, or lung resection for non-small cell lung cancer);\n* Use of an electrical mechanical device for airway clearance during the study period (in-exsufflator, high-frequency chest oscillation, etc.);\n* Active cancer;\n* Severe episode of hemoptysis in the last 3 months;\n* Severe tracheomalacia.\n\nExclusion Criteria:\n\n* Withdrawal of consent;\n* Acute COPD exacerbation between visits or onset of cardiorespiratory instability;\n* Use of an electrical mechanical device for airway clearance during the study period (in-exsufflator, high-frequency chest oscillation, etc.).",{"count":394,"type":22},33,[25],"Chronic obstructive pulmonary disease is a long-term lung condition that causes breathing difficulties. People living with this disease often feel short of breath, especially during physical activity, which can make daily tasks more challenging. This breathlessness is partly caused by mucus accumulation within the airways and air getting trapped in the lungs. Both of these reduce the amount of fresh air that can enter with each breath and increase the effort required to breathe.\n\nTo manage symptoms, people with chronic obstructive pulmonary disease may use medications, oxygen therapy, or be referred to pulmonary rehabilitation programs. These programs often include exercise training, self-management strategies, and airway clearance techniques. While chest physiotherapists typically guide patients in these techniques, certain medical devices can also help individuals manage their condition independently at home.\n\nOne such device uses a method called intermittent intrapulmonary deflation, which involves applying gentle pressure changes through a mouthpiece to help loosen mucus and release trapped air from the lungs. Although some individuals already use this kind of device as part of their daily care, more scientific evidence is needed to determine whether the improvements in airway clearance and reduced air trapping actually lead to measurable relief of breathlessness.\n\nThe goal of this clinical trial is to find out whether this type of medical device designed to remove airway mucus and trapped air in the lungs (using intermittent intrapulmonary deflation) can help reduce breathlessness (dyspnea) after physical activity in people with COPD.\n\nThe main questions this study aims to answer are:\n\n* Does using the device at home for one week reduce the intensity of breathlessness after walking?\n* Does it also improve walking distance, reduce the feeling of muscle fatigue, or increase satisfaction with the airway clearance method?\n\nResearchers will compare the active device to a placebo device that looks and feels identical but does not deliver the active treatment. This comparison will help determine whether the observed effects are due to the device itself or other factors such as expectations or chance.\n\nParticipants in this study will be adults diagnosed with moderate to very severe chronic obstructive pulmonary disease. All participants must have recently completed a pulmonary rehabilitation program, continue to experience breathlessness while walking, and show signs of lung hyperinflation (when air remains trapped in the lungs). People will not be included if they have other serious health conditions that could make walking difficult or unsafe, or if they have any contraindications to using the device.\n\nParticipants who agree to participante in the study will:\n\n* Attend a visit at the pulmonary rehabilitation center for baseline testing and to learn how to use the device;\n* Be randomly assigned to use either the active device or the placebo device at home for 7 days;\n* Return to the center for walking tests, lung function tests, and questionnaires about breathing and fatigue;\n* After a one-week break, use the device with alternative settings (the one not used in the first phase) for another 7 days;\n* Complete a final visit at the end of the study to repeat the same tests.\n\nParticipants will also be invited to take part in an ancillary study during their first clinic visit to examine how a single session with the device affects breathlessness immediately after walking.\n\nThis research will help determine whether this non-pharmacological, device-based method of clearing mucus and reducing trapped air can bring meaningful improvement in breathlessness for people with chronic obstructive pulmonary disease, especially when used at home. If effective, it may offer a simple and convenient way to help people breathe more comfortably during everyday activities.\n\nParticipants will receive compensation for their time and travel.",[28],[87,399,400,401,402],"Chronic obstructive pulmonary disease","Intermittent intrapulmonary deflation","Dypsnea","Exercise","2026-06-01",{"date":405,"type":37},"2026-06-02",{"date":407,"type":37},"2025-06-01",{"date":409,"type":22},"2028-02-28",{"name":411,"class":44},"ADIR Association",{"id":413,"slug":414,"hasResults":12,"nctId":415,"briefTitle":416,"officialTitle":417,"acronym":418,"eligibilityCriteria":419,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":314,"enrollmentInfo":420,"targetDuration":4,"studyType":288,"phases":4,"briefSummary":422,"conditions":423,"keywords":424,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":300,"lastUpdatePostDateStruct":426,"startDateStruct":428,"completionDateStruct":430,"leadSponsor":432,"locationsCount":45},"100616605","study-of-patient-with-frequent-exacerbations-in-moscow-100616605","NCT07307781","Study of Patient With Frequent Exacerbations in Moscow","Clinical and dEmographic chaRacteristics of Patients With Frequent COPD Exacerbations and Evaluation of Therapeutic Approaches in Treatment in Moscow","CERERA-MOSCOW","Inclusion Criteria:\n\n1. Age ≥18 years at the time of inclusion;\n2. Signed and dated written informed consent in accordance with ICH GCP and local law prior to inclusion in the study;\n3. Confirmed diagnosis of moderate-to-very severe (GOLD 2-4) COPD established by spirometry demonstrating a post-bronchodilator ratio of forced expiratory volume in 1 second (FEV1) to forced vital capacity (FVC) \\\u003C0.7 obtained outside an exacerbation;\n4. ≥2 moderate or ≥1 severe COPD exacerbations in previous 52 weeks;\n5. Dual inhaled maintenance therapy (LABA\u002FLAMA, ICS\u002FLAMA, or ICS\u002FLABA) for at least 6 weeks prior to screening\n\nExclusion Criteria:\n\n1. Current or previous treatment with triple combination (ICS\u002FLAMA\u002FLABA) as maintenance therapy within 52 weeks prior to screening visit;\n2. COPD due to documented alpha-1-antitrypsin deficiency;\n3. A diagnosis of bronchiectasis, sarcoidosis, interstitial lung diseases, or idiopathic pulmonary fibrosis, exacerbation of asthma or any acute or chronic disease that, as deemed by Investigator, limits the ability of patients to participate in this study or could influence the interpretation of the results;\n4. The participation in any interventional clinical study currently or within 52 weeks prior to inclusion; participation in non-interventional, observational registries without protocol-driven treatment changes does not constitute an exclusion",{"count":421,"type":22},500,"This Study is multicenter, non-interventional, ambispective registry to evaluate the demographic and clinical characteristics, therapeutic approaches and outcomes in COPD outpatients with frequent exacerbations in Moscow",[28],[425],"chronic obstructive pulmonary disease (COPD)",{"date":427,"type":37},"2026-05-29",{"date":429,"type":37},"2025-11-28",{"date":431,"type":22},"2027-06-25",{"name":100,"class":101},{"id":434,"slug":435,"hasResults":12,"nctId":436,"briefTitle":437,"officialTitle":437,"acronym":438,"eligibilityCriteria":439,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":440,"targetDuration":4,"studyType":23,"phases":442,"briefSummary":443,"conditions":444,"keywords":448,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":452,"lastUpdatePostDateStruct":453,"startDateStruct":455,"completionDateStruct":457,"leadSponsor":459,"locationsCount":461},"100638293","feasibility-study-of-a-digital-interactive-life-style-platform-for-individuals-after-rehabilitation-100638293","NCT07597031","Feasibility Study of a Digital Interactive Life-style Platform for Individuals After Rehabilitation","Feas Platf","Inclusion Criteria:\n\n* Adults (≥18 years)\n* 10 or less days before discharge from inpatient rehabilitation at the Bern Rehab Center in Heiligenschwendi or the Insel Hospital (both belonging to the Insel Group)\n* Belonging to one of the following clinical cohorts: acute coronary syndrome or ischemic heart failure; chronic obstructive pulmonary disease (COPD) - clinically diagnosed and confirmed by pulmonary specialist; fragility fracture - e.g., hip fracture or other low-energy fractures; minor stroke, clinically confirmed ischemic or hemorrhagic stroke with mild neurological deficits.\n* Able to provide informed consent.\n* Access to and ability to use a device that has internet access (e.g., tablet, smartphone, laptop, etc.).\n\nExclusion Criteria:\n\n* Cognitive or psychiatric condition interfering with consent or use of the app.\n* Physical disability preventing digital device use without support.\n* Heavy language production or comprehension impairments.",{"count":441,"type":22},240,[25],"The goal of this clinical trial is to evaluate the feasibility and usability of a digital lifestyle platform designed to support patients after discharge from inpatient rehabilitation. It will also assess patient engagement and the potential of the platform to support long-term self-management and healthy lifestyle behaviors in an outpatient setting.\n\nThe main questions it aims to answer are:\n\nIs the platform feasible and acceptable for patients after rehabilitation? Do patients engage with and regularly use the platform over time? Can personalized digital recommendations support adherence to healthy behaviors and self-management?\n\nResearchers will evaluate a telemedicine platform that delivers individualized suggestions, including lifestyle applications, educational content, and advice from healthcare professionals. The content is tailored to patient needs and continuously adapted based on patient feedback.\n\nParticipants will:\n\nUse the digital platform after discharge from inpatient rehabilitation for a defined follow-up period Receive personalized recommendations through the platform Rate the usefulness of recommendations to enable continuous adaptation Attend study visits or remote assessments to evaluate usability, engagement, and outcomes Continue standard outpatient care alongside the intervention",[28,445,446,447],"Acute Coronary Syndrome","Fragility Fracture","Minor Stroke",[449,450,451],"Telemedicine","Phase III rehabilitation","Long-term non-communicable diseases","2026-05-18",{"date":454,"type":37},"2026-05-19",{"date":456,"type":22},"2026-05-01",{"date":458,"type":22},"2027-02-01",{"name":460,"class":44},"Matthias Wilhelm, MD",2,{"id":463,"slug":464,"hasResults":12,"nctId":465,"briefTitle":466,"officialTitle":467,"acronym":4,"eligibilityCriteria":468,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":469,"targetDuration":4,"studyType":288,"phases":4,"briefSummary":470,"conditions":471,"keywords":473,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":478,"lastUpdatePostDateStruct":479,"startDateStruct":481,"completionDateStruct":483,"leadSponsor":485,"locationsCount":45},"100639546","d-rsbi-versus-rsbi-for-predicting-weaning-success-in-copd-patients-100639546","NCT07590362","D-RSBI Versus RSBI for Predicting Weaning Success in COPD Patients","Diaphragmatic Rapid Shallow Breathing Index (D-RSBI) Versus Traditional Rapid Shallow Breathing Index (RSBI) for Prediction of Weaning Success From Mechanical Ventilation in COPD Patients","Inclusion Criteria:\n\n* Mechanically ventilated COPD patients fulfilling standard weaning readiness criteria.\n* Invasive mechanical ventilation for more than 24 hours before spontaneous breathing trial.\n* Hemodynamically stable without significant vasopressor support.\n* Adequate oxygenation with FiO2 ≤ 0.5 and PEEP ≤ 8 cmH2O .\n* Preserved mental status and ability to initiate spontaneous breathing.\n* Successful tolerance of spontaneous breathing trial conducted on CPAP mode with pressure support ≤ 8 cmH2O.\n\nExclusion Criteria:\n\n* Refusal of consent\n* Neuromuscular disease, phrenic nerve palsy, or diaphragmatic paralysis.\n* Large pneumothorax or pathology interfering with ultrasound assessment.\n* Terminal extubation.\n* Recent major thoracic surgery.\n* Poor sonographic window despite repeated attempts.",{"count":21,"type":22},"This prospective observational cohort study aims to compare the predictive accuracy of diaphragmatic rapid shallow breathing index (D-RSBI) versus traditional rapid shallow breathing index (RSBI) for predicting weaning success from invasive mechanical ventilation in COPD patients. Diaphragmatic ultrasound measurements will be performed during spontaneous breathing trials, and patients will be followed for 72 hours after extubation to assess weaning outcomes.",[28,472],"Mechanical Ventilator Weaning",[474,475,87,476,477],"D-RSBI","RSBI","Diaphragm Ultrasound","Mechanical Ventilation Weaning","2026-05-14",{"date":480,"type":37},"2026-05-15",{"date":482,"type":37},"2026-04-15",{"date":484,"type":22},"2027-06",{"name":486,"class":44},"Sohag University",{"id":488,"slug":489,"hasResults":12,"nctId":490,"briefTitle":491,"officialTitle":492,"acronym":4,"eligibilityCriteria":493,"healthyVolunteers":12,"sex":17,"minAge":79,"maxAge":4,"enrollmentInfo":494,"targetDuration":4,"studyType":23,"phases":496,"briefSummary":497,"conditions":498,"keywords":499,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":502,"lastUpdatePostDateStruct":503,"startDateStruct":504,"completionDateStruct":506,"leadSponsor":508,"locationsCount":45},"100638665","investigation-of-the-effect-of-structured-energy-conservation-techniques-training-on-copd-patients-100638665","NCT07581132","Investigation of the Effect of Structured Energy Conservation Techniques Training on COPD Patients","Investigation of the Effects of Structured Energy Conservation Techniques Training on Activities of Daily Living, Fatigue, and Exercise Capacity in COPD Patients","Inclusion Criteria:\n\n* Patients who have been admitted to the pulmonary diseases ward or have applied to the pulmonary diseases outpatient clinic,\n* Patients diagnosed with COPD,\n* Patients in category E of the GOLD A, B, E classification (patients experiencing more than 2 moderate exacerbations or having multiple hospitalizations) (GOLD, 2025)\n* Patients over 40 years of age (Adeloye et al, 2015).\n* Patients who will continue their health check-ups at the Isparta City Hospital Pulmonology Outpatient Clinic,\n* Patients who agree to participate in the study,\n* Patients or at least one of their relatives who can read and write,\n* Patients or at least one of their relatives who does not have communication problems will be included in the study.\n\nExclusion Criteria:\n\n* Patients with serious orthopedic problems that may have a significant impact on daily activities,\n* Patients with progressive neuromuscular disease,\n* Patients who have experienced unstable angina pectoris or myocardial infarction within the last month,\n* Patients living alone,\n* Patients in groups A and B of the GOLD ABE classification will not be included. For patients in group A, mMRC 0-1, CAT\\\u003C10 are used as criteria; for patients in group B, mMRC≥2, CAT≥10 are used as criteria (GOLD, 2025).",{"count":495,"type":22},70,[25],"Chronic obstructive pulmonary disease (COPD) is a heterogeneous lung disease characterized by chronic respiratory symptoms (dyspnea, cough, sputum production, and\u002For exacerbations) due to persistent, often progressive airflow obstruction resulting from abnormalities in the airways (bronchiolitis, bronchitis) and\u002For alveoli (emphysema). COPD is a multifaceted disease that is not limited to respiratory symptoms but also negatively affects individuals' functional capacity, physical endurance, and participation in daily living activities. Common symptoms include shortness of breath (dyspnea) and a significant feeling of fatigue; this can lead to decreased exercise capacity, limitations in daily living activities, and ultimately dependence over time. Therefore, in the treatment of COPD, not only drug therapy but also interventions aimed at symptom control and improving functional capacity are becoming increasingly important. Energy conservation techniques, included in pulmonary rehabilitation programs, are based on the view that dyspnea occurs most intensely during daily living activities, and that performing these activities in an energy-conserving manner will result in less dyspnea. Energy conservation techniques are one of the trainings given to improve symptom management in COPD patients. Disease symptoms can increase in COPD patients during tasks such as washing hair, drying hair, shaving, reaching, bending, lifting, carrying, pushing, and pulling weights. When appropriate body mechanics and tools that facilitate tasks are used, the amount of energy required during these tasks decreases. In this way, it is thought that patients will be more active in their daily living activities. Breathing exercises are also a component of pulmonary rehabilitation and support the increase of respiratory muscle function and exercise tolerance. Accordingly, it is thought that structured energy conservation techniques training can improve daily living activities, fatigue, and exercise capacity in COPD patients. This research will be conducted as a pre-test-post-test, single-blind, randomized controlled trial to examine the effect of structured energy conservation techniques training on daily living activities, fatigue, and exercise capacity in COPD patients.",[28],[500,87,501],"Activities of Daily Living","Energy Conservation","2026-05-12",{"date":478,"type":37},{"date":505,"type":22},"2026-07-10",{"date":507,"type":22},"2027-01-10",{"name":509,"class":44},"Akdeniz University",{"id":511,"slug":512,"hasResults":12,"nctId":513,"briefTitle":514,"officialTitle":515,"acronym":516,"eligibilityCriteria":517,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":518,"targetDuration":4,"studyType":23,"phases":520,"briefSummary":521,"conditions":522,"keywords":523,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":531,"lastUpdatePostDateStruct":532,"startDateStruct":533,"completionDateStruct":534,"leadSponsor":536,"locationsCount":45},"100613250","assessing-and-improving-misuse-of-inhalers-in-copd-outpatients-100613250","NCT07264140","Assessing and Improving Misuse of Inhalers in COPD Outpatients","Assessing and Improving Misuse of Inhalers in Outpatients With COPD - The AIMO COPD Study","AIMO COPD","Inclusion Criteria:\n\n1. Age ≥18 years\n2. COPD confirmed by spirometry (FEV1\u002FFVC \\\u003C0.7)\n3. Current use of at least one maintenance inhaler\n4. Follow-up at the outpatient pneumology clinic of HFR Fribourg\n5. Ability to provide written informed consent\n\nExclusion Criteria:\n\n1. Inability to provide informed consent (e.g. severe cognitive impairment, advanced psychiatric disorder, unresolved language barrier)\n2. Life expectancy \\\u003C12 months\n3. Predominant other chronic lung disease (e.g. asthma, fibrosis)\n4. Any condition preventing completion of study procedures\n5. Ongoing participation in another interventional trial on inhaler technique",{"count":519,"type":22},116,[25],"Chronic obstructive pulmonary disease (COPD) is a common long-term lung disease that causes breathlessness, cough, and frequent flare-ups. Most patients with COPD use inhaled medications every day. However, many people do not use their inhalers correctly, or they cannot generate the right inspiratory flow for their device. When inhalers are used incorrectly, the medication does not reach the lungs properly, symptoms worsen, and the risk of exacerbations increases.\n\nThis pragmatic randomized controlled trial evaluates whether a structured physiotherapist-led inhaler optimization program improves inhaler use in routine outpatient COPD care. The program is delivered by trained physiotherapists over 12 months and includes three in-person sessions. During these sessions, the physiotherapist evaluates the patient's inhaler technique using placebo devices, measures the patient's peak inspiratory flow with the In-Check DIAL® device, and provides individualized \"teach-to-goal\" education to help patients use their inhalers correctly. If the patient continues to make critical errors or cannot generate the appropriate inspiratory flow for their inhaler, the physiotherapist may recommend adapting the type of inhaler to better match the patient's abilities.\n\nParticipants will be randomly assigned to one of two groups. The intervention group will receive the structured program in addition to their usual COPD care. The control group will continue with usual outpatient care without the physiotherapist-led sessions. All participants will complete baseline and 12-month assessments, which include inhaler technique evaluation, inspiratory flow measurement, respiratory questionnaires, and lung function tests. Telephone follow-up calls will be performed at months 2, 5, and 8 to monitor symptoms, inhaler use, and adherence.\n\nThe main outcome of the study is the proportion of inhalers used incorrectly at 12 months. Incorrect use is defined as at least one critical inhaler technique error or an inspiratory flow that is too low or too high for the patient's device. Secondary outcomes include changes in respiratory symptoms, health status, adherence to inhaled treatment, patient satisfaction with inhalers, confidence in inhaler use, and the number of COPD exacerbations or hospitalizations during the study.\n\nThis research may help improve everyday inhaler use in people with COPD and support more personalized inhaler selection in routine clinical care. Although participants may not benefit directly, the study poses minimal risks and may contribute to future improvements in COPD management.",[28],[87,217,524,525,526,527,528,194,529,530],"Inhaler Technique","Inhaler Misuse","Peak Inspiratory Flow","Inhaler Education","Inhaler Optimization","In-Check DIAL","Outpatient COPD Care","2026-05-11",{"date":478,"type":37},{"date":403,"type":22},{"date":535,"type":22},"2029-12-31",{"name":537,"class":44},"Hôpital Fribourgeois",{"id":539,"slug":540,"hasResults":12,"nctId":541,"briefTitle":542,"officialTitle":543,"acronym":544,"eligibilityCriteria":545,"healthyVolunteers":12,"sex":17,"minAge":79,"maxAge":4,"enrollmentInfo":546,"targetDuration":4,"studyType":23,"phases":548,"briefSummary":550,"conditions":551,"keywords":552,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":558,"lastUpdatePostDateStruct":559,"startDateStruct":560,"completionDateStruct":562,"leadSponsor":564,"locationsCount":4},"100639364","phase-4-this-after-market-study-is-seeing-if-dupilumab-plus-usual-standard-of-care-soc-is-better-than-usual-care-alone-for-adult-participants-after-a-severe-chronic-obstructive-pulmonary-disease-copd-flare-up-requiring-hospitalization-100639364","NCT07587658","This After Market Study is Seeing if Dupilumab Plus Usual Standard of Care (SOC) is Better Than Usual Care Alone for Adult Participants After a Severe Chronic Obstructive Pulmonary Disease (COPD) Flare-Up Requiring Hospitalization","A Randomized, Double-Blind, Placebo-Controlled Study Comparing the Efficacy of Dupilumab Added on to Standard of Care (SOC) Treatment vs SOC Treatment Following Hospitalization for a COPD Exacerbation","MISSION","Key Inclusion Criteria:\n\n1. Has a clinical diagnosis of COPD prior to randomization, as defined in the protocol\n2. Hospitalized or admitted to the ED \\>24 hours (from time of first admission or presentation to the ED) for acute exacerbation of COPD as primary diagnosis according to the principal investigator and exacerbation is managed by Systemic Corticosteroids (SCS) ± antibiotics and other appropriate treatments as per SOC\n3. Elevated blood eosinophil counts during the current exacerbation, as defined in the protocol. The exacerbation event starts from the day Systemic Corticosteroids (SCS) ± antibiotics are administered continuously up to the day they presented to ED\u002Fhospital\n\nKey Exclusion Criteria:\n\n1. Clinical evidence of pneumonia as the primary cause of admission in the investigator's opinion or acquired during hospital stay\n2. Complicating pulmonary conditions during the 8 weeks prior to randomization which may confound treatment assessments, as defined in the protocol\n3. Clinically significant pulmonary diseases other than COPD which may impair lung function and interfere with treatment assessments\n4. Participants with clinically significant α-1 anti-trypsin deficiency which may impair lung function and interfere with treatment assessments\n5. Cardiac-related comorbidity, as defined in the protocol\n6. Treatment with invasive mechanical ventilation in-hospital during the index event, as defined in the protocol\n7. Any biologic therapy or biologic Investigational Medicinal Product (IMP) to treat type 2 inflammatory diseases within 6 months prior to the screening visit or 5 half-lives, whichever is longer, as defined in the protocol\n\nNOTE: Other Protocol-defined Inclusion\u002FExclusion Criteria Apply",{"count":547,"type":22},754,[549],"PHASE4","This study is researching a drug called dupilumab, referred to as \"study drug\". The study is focused on people diagnosed with COPD to determine if the study drug, in addition to standard of care treatment for COPD, might reduce the reoccurrence of a COPD exacerbation (a \"flare-up\") happening within the study treatment duration (around 90 days).\n\nThe study is looking at another research question:\n\n• What side effects may happen from taking the study drug",[28],[553,554,555,556,557],"Moderate and\u002For Severe Exacerbation","Eosinophilic phenotype","Elevated blood eosinophil counts","Type 2 inflammation","dupilumab","2026-05-08",{"date":478,"type":37},{"date":561,"type":22},"2026-06-30",{"date":563,"type":22},"2028-07-30",{"name":565,"class":101},"Regeneron Pharmaceuticals",{"id":567,"slug":568,"hasResults":12,"nctId":569,"briefTitle":570,"officialTitle":571,"acronym":4,"eligibilityCriteria":572,"healthyVolunteers":12,"sex":17,"minAge":79,"maxAge":4,"enrollmentInfo":573,"targetDuration":4,"studyType":23,"phases":575,"briefSummary":576,"conditions":577,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":199,"lastUpdatePostDateStruct":579,"startDateStruct":581,"completionDateStruct":583,"leadSponsor":585,"locationsCount":461},"100581188","pulmonary-rehabilitation-for-rural-patients-with-copd-100581188","NCT06847061","Pulmonary Rehabilitation for Rural Patients With COPD","Decreasing Disparity in Lung Disease: Pulmonary Rehabilitation for Rural Patients With COPD","Inclusion Criteria\n\n* 40 years of age or older\n* Physician-diagnosed COPD\n* Living in a rural area defined by Rural-Urban Commuting Area Codes 4-10\n* mMRC score\\>=1\n* English Speaking\n\nExclusion Criteria\n\n* Inability to walk (orthopedic\u002Fneurologic\u002Fcardiac limitation causing immobility)\n* Cognitive impairment or inability to understand and follow instructions.\n* Patients with no COPD symptom burden, no breathlessness (mMRC score 0), as based on our previous studies they usually perceive no benefit from PR and do not have compliance with PR.\n* Traditional center-based PR was completed within 3 months of initial study recruitment.\n* Transition to hospice or end-of-life care at the time of screening.\n* Acute exacerbation at the time of screening.",{"count":574,"type":22},306,[25],"The purpose of this study is to test the uptake, effectiveness, and patient-caregiver-provider experience of a crucial treatment not provided in rural areas: pulmonary rehabilitation.",[578],"Chronic Obstructive Pulmonary Disease (COPD",{"date":580,"type":37},"2026-05-07",{"date":582,"type":37},"2025-04-01",{"date":584,"type":22},"2029-08-31",{"name":586,"class":44},"Mayo Clinic",{"id":588,"slug":589,"hasResults":12,"nctId":590,"briefTitle":591,"officialTitle":592,"acronym":4,"eligibilityCriteria":593,"healthyVolunteers":12,"sex":17,"minAge":79,"maxAge":4,"enrollmentInfo":594,"targetDuration":4,"studyType":23,"phases":596,"briefSummary":597,"conditions":598,"keywords":600,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":604,"lastUpdatePostDateStruct":605,"startDateStruct":606,"completionDateStruct":608,"leadSponsor":609,"locationsCount":45},"100640790","phase-1-impact-of-eradication-therapy-on-helicobacter-pylori-infection-with-chronic-obstructive-pulmonary-disease-100640790","NCT07574879","Impact of Eradication Therapy on Helicobacter Pylori Infection With Chronic Obstructive Pulmonary Disease:","Impact of Eradication Therapy on Helicobacter Pylori Infection in Patients With Chronic Obstructive Pulmonary Disease: A Prospective Study","Inclusion Criteria:\n\n* Adults aged ≥40 years.\n* Diagnosed with COPD confirmed by spirometry (post-bronchodilator FEV1\u002FFVC \\\u003C 0.70) and H. pylori positive.\n* Willing to participate and provide consent for testing and follow-up.\n\nExclusion Criteria:\n\n* patients with asthma, known peptic ulcers, acute exacerbation of COPD\n* patients who took antibiotics and PPIs within the last month,\n* Patients who took histamine-2-receptor antagonists within the last week or antacid within the last 24 hours a\n* those having H. pylori eradication treatment within the last 6 months",{"count":595,"type":22},54,[129],"Helicobacter pylori (HP) is a well-established pathogen responsible for chronic gastritis and peptic ulcer disease. Its presence has been implicated in the development of gastric malignancies such as adenocarcinoma and mucosa-associated lymphoid tissue lymphoma. Chronic H. pylori infection is associated with systemic inflammatory responses and various extra gastric diseases, including cardiovascular, metabolic, and neurological disorders. Furthermore, H. pylori infection contributes to gastrointestinal dysbiosis by interacting with gastrointestinal microbiota, which may be involved in gastric carcinogenesis and other systemic disorders. Growing evidence highlights the role of dysbiosis in chronic respiratory diseases, such as chronic obstructive pulmonary disease (COPD) and asthma. Emerging epidemiological evidence suggests a potential association between H. pylori infection and respiratory diseases, including COPD. Several observational studies and meta-analyses have found that H. pylori infection in patients with COPD may be associated with systemic inflammatory markers and altered pulmonary function parameters. Despite these associations, the causal mechanisms underlying this relationship remain unclear. Furthermore, it is uncertain whether eradication of H. pylori yields measurable benefits on clinical outcomes in COPD patients. So, Our aim to evaluate changes in symptoms, pulmonary function, and inflammatory markers after H. pylori eradication therapy in the H. pylori-positive COPD patients.\n\nan intervention study (quasi experimental), study will be carried out in the inpatient and outpatient clinics of Chest Department, Faculty of Medicine, Zagazig University hospitals.\n\nPatients included in the study:\n\nwell controlled COPD patients attending outpatient clinics for a period of 6 months fulfilling inclusion and exclusion criteria will be included in this study.",[28,599],"With Poitive H Pylori",[601,602,603],"Chronic Obstructive Pulmonary disease","Helicobacter Pylori","eradication therapy","2026-05-03",{"date":558,"type":37},{"date":607,"type":37},"2026-03-01",{"date":201,"type":22},{"name":610,"class":70},"Zagazig University",{"id":612,"slug":613,"hasResults":12,"nctId":614,"briefTitle":615,"officialTitle":616,"acronym":617,"eligibilityCriteria":618,"healthyVolunteers":12,"sex":17,"minAge":79,"maxAge":4,"enrollmentInfo":619,"targetDuration":4,"studyType":23,"phases":621,"briefSummary":622,"conditions":623,"keywords":624,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":629,"lastUpdatePostDateStruct":630,"startDateStruct":631,"completionDateStruct":633,"leadSponsor":635,"locationsCount":4},"100638094","effect-of-pursed-lip-breathing-with-different-ie-ratios-on-respiratory-outcomes-in-copd-patients-100638094","NCT07573826","Effect of Pursed-Lip Breathing With Different I:E Ratios on Respiratory Outcomes in COPD Patients","Effectiveness of Different Inspiratory-Expiratory Ratios (1:3, 1:4, and 1:5) in Pursed-Lip Breathing on Respiratory Rate, Oxygen Saturation, and Dyspnea in Patients With Chronic Obstructive Pulmonary Disease: A Quasi-Experimental Study","PLB I:E Ratio","Inclusion Criteria:\n\n* Diagnosed with stable COPD\n* Age ≥ 40 years\n* Able to follow breathing instructions\n* Willing to participate and provide informed consent\n\nExclusion Criteria:\n\n* Cognitive impairment or decreased consciousness\n* Severe cardiovascular disease (heart failure, coronary artery disease, pulmonary hypertension)\n* Asthma-COPD overlap (ACO)\n* Acute respiratory infection (e.g., pneumonia)\n* Neuromuscular disorders affecting respiratory muscles",{"count":620,"type":22},122,[25],"The goal of this clinical trial is to evaluate whether different inspiratory-expiratory (I:E) ratios in the pursed-lip breathing (PLB) technique can improve respiratory outcomes in patients with stable Chronic Obstructive Pulmonary Disease (COPD) aged 40 years and older. The primary purpose is to determine whether a specific breathing intervention can improve respiratory function.\n\nThe main questions it aims to answer are:\n\nDoes PLB with different I:E ratios (1:3, 1:4, and 1:5) reduce respiratory rate in COPD patients? Does PLB with different I:E ratios improve oxygen saturation and reduce dyspnea severity?\n\nResearchers will compare PLB with I:E ratios of 1:3, 1:4, and 1:5 and a control group receiving standard care to see if different ratios produce different effects on respiratory rate, oxygen saturation, and dyspnea levels.\n\nParticipants will:\n\nPerform pursed-lip breathing using assigned I:E ratios (1:3, 1:4, or 1:5) for 10 minutes Be assigned to either an intervention group or a control group (standard care) Have their respiratory rate measured before and after the intervention Have their oxygen saturation measured using a pulse oximeter Report their dyspnea level using the Modified Borg Scale before and after the intervention",[28],[625,626,627,628],"Pursed-Lip Breathing I:E ratio in COPD","Oxygen saturation","dyspnea scale","respiratory rate","2026-04-30",{"date":580,"type":37},{"date":632,"type":22},"2026-05-04",{"date":634,"type":22},"2026-08-14",{"name":636,"class":44},"Scholastica Fina Aryu Puspasari",{"id":638,"slug":639,"hasResults":12,"nctId":640,"briefTitle":641,"officialTitle":641,"acronym":642,"eligibilityCriteria":643,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":644,"targetDuration":4,"studyType":288,"phases":4,"briefSummary":646,"conditions":647,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":629,"lastUpdatePostDateStruct":648,"startDateStruct":650,"completionDateStruct":651,"leadSponsor":652,"locationsCount":4},"100636800","breztri-regulatory-post-marketing-surveillance-in-korea-100636800","NCT07570394","BREZTRI REGULATORY POST MARKETING SURVEILLANCE IN KOREA","Breztri rPMS","Inclusion Criteria:\n\n1. Patients who have been diagnosed with COPD.\n2. Patients who have newly initiated treatment with Breztri according to the approved label in Korea\n3. Provision of signed and dated written informed consent by the patient or legally acceptable representative\n\nExclusion Criteria:\n\n1. Other off-label indications outside of the locally approved prescribing information\n2. Pregnant and\u002For breast feeding\n3. Current participation in any interventional trial",{"count":645,"type":22},600,"As part of a post-approval commitment requested by the Ministry of Food and Drug Safety (MFDS), this open-label, single-arm, multicentre, observational Post-Marketing Surveillance (PMS) study aims to characterize the safety profile of Breztri in real-world clinical practice settings, either confirming known safety outcomes or identifying previously unsuspected adverse drug reactions. The study will also evaluate effectiveness of Breztri in real-world clinical practice settings, generating essential clinical evidence from a broader and more diverse Korean patient population representative of daily medical practice.",[28],{"date":649,"type":37},"2026-05-06",{"date":41,"type":22},{"date":138,"type":22},{"name":100,"class":101},"Chronic Obstructive Pulmonary Disease, COPD"]